Background/Objectives: Little information has been published on patients diagnosed with brain metastasis secondary to lung cancer. Correlating outcome patterns (hospice care, lost to follow-up, death before hospice care or treatment) and specific characteristics of treated and untreated patients may identify subsets of patients who may benefit from treatment.Methods: We evaluated data from the Kentucky Cancer Registry and identified 284 cases who were diagnosed with brain metastasis secondary to non-small cell lung cancer (NSCLC) between 1 August 2016, and 31 December 2019. We evaluated type and timing of treatment received, as well as focused on those patients who did not receive treatment. For those patients who did not receive treatment, various characteristics that may have impacted their decision or ability to undergo follow-up were also evaluated. This included social history, disease burden, as well as oncology treatment timelines. Lastly, due to the high smoking rate in Kentucky, we conducted an analysis of patient tobacco use.Results: Our results show that 61 cases (21.8%) never received treatment for lung cancer with brain metastasis. Further analysis of the non-treated cases demonstrated that 19 cases (31.1%) never met with an oncology team while in the hospital or after discharge; 14 of the 61 cases (23.0%) were too sick to receive treatment and died prior to having the option of treatment; and 47 of the 61 cases (77.0%) may have had the option of treatment but declined.Conclusions: Historically, patients with brain metastases have faced poor prognoses and limited treatment options. However, advancements in systemic chemoimmunotherapy and targeted therapies have introduced new treatment possibilities, offering improved symptom control and the potential for prolonged survival. This analysis is crucial for identifying potential barriers to care, optimizing resource allocation, and guiding future research.
背景/目的：目前关于肺癌继发脑转移患者的已发表信息较少。通过分析治疗与未治疗患者的结局模式（临终关怀、失访、临终关怀或治疗前死亡）及其具体特征，可能识别出能从治疗中获益的患者亚群。 方法：我们评估了肯塔基州癌症登记处的数据，确定了2016年8月1日至2019年12月31日期间诊断为非小细胞肺癌（NSCLC）继发脑转移的284例病例。我们评估了患者接受治疗的类型和时机，并重点关注未接受治疗的患者群体。针对未治疗患者，进一步分析了可能影响其接受随访决策或能力的各项特征，包括社会史、疾病负荷以及肿瘤治疗时间线。最后，鉴于肯塔基州较高的吸烟率，我们对患者的烟草使用情况进行了专项分析。 结果：研究显示61例（21.8%）脑转移肺癌患者从未接受过治疗。对未治疗病例的深入分析表明：19例（31.1%）在住院期间或出院后从未接触过肿瘤治疗团队；61例中有14例（23.0%）因病情过重在获得治疗选择前死亡；而61例中有47例（77.0%）虽具备治疗条件但选择放弃治疗。 结论：历史上脑转移患者普遍面临预后不良和治疗选择有限的困境。然而，全身性化学免疫疗法和靶向治疗的进展为这类患者带来了新的治疗可能，既能改善症状控制，又为延长生存期提供了潜在机会。本分析对于识别潜在医疗障碍、优化资源配置以及指导未来研究方向具有重要意义。
肿瘤(癌症)患者之家